Data from A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma

• DOI: 10.1158/1078-0432.c.6530820.v1
• Publication Date: 2023-04-01T02:09:01Z
• Authors: Jethro L. Hu; Oluwaseun A. Omofoye; Jeremy D. Rudnick; Sungjin Kim; Mourad Tighiouart; Surasak Phuphanich; Hongqiang Wang; Mia Mazer; Toni Ganaway; Ray M. Chu; Chirag G. Patil; Keith L. Black; Stephen L. Shiao; Rongfu Wang; John S. Yu
• Keywords: Temozolomide; Tolerability; ELISPOT; Progression-free survival

<div>AbstractPurpose:<p>Glioblastoma (GBM) is a heterogeneous malignancy with multiple subpopulations of cancer cells present within any tumor. We the results phase I clinical trial using an autologous dendritic cell (DC) vaccine pulsed lysate derived from GBM stem-like line.</p>Patients and Methods:<p>Patients newly diagnosed recurrent were enrolled as separate cohorts. Eligibility criteria included qualifying surgical resection or minimal tumor size, ≤ 4-mg dexamethasone daily dose, Karnofsky score ≥70. Vaccine treatment consisted two phases: induction given weekly for 4 weeks, maintenance vaccines administered every 8 weeks until depletion supply disease progression. Patients also received standard-of-care radiation temozolomide. The primary objective this open-label, single-institution was to assess safety tolerability DC vaccine.</p>Results:<p>For 11 patients GBM, median progression-free survival (PFS) 8.75 months, overall 20.36 months. For 25 PFS 3.23 6-month 24%, 11.97 A subset developed cytotoxic T-cell response determined by IFNγ ELISpot assay.</p>Conclusions:<p>In trial, allogeneic line safe well tolerated. Clinical outcomes add body evidence suggesting that immunotherapy plays role in GBM.</p></div>